title: Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
abstract: We report the use of anti-interleukin-5 (mepolizumab) during an 18-month period in a pediatric hypereosinophilic syndrome. Infusions every 3 months allowed better control of hypereosinophilic syndrome flares and maintained blood eosinopenia with significantly less steroid use compared with all other therapies (prednisolone alone, interferon alpha, or imatinib mesylate).
authors.affiliation: Department of Allergy & Immunology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
authors.forename: Sam
authors.initials: S
authors.lastname: Mehr
authors.forename: Sylvan
authors.initials: S
authors.lastname: Rego
authors.forename: Alyson
authors.initials: A
authors.lastname: Kakakios
authors.forename: Henry
authors.initials: H
authors.lastname: Kilham
authors.forename: Andrew
authors.initials: A
authors.lastname: Kemp
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002648:Child; D004804:Eosinophils / Q000166:cytology; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D000068877:Imatinib Mesylate; D007262:Infusions, Intravenous; D015848:Interleukin-5 / Q000037:antagonists & inhibitors / Q000276:immunology*; D007958:Leukocyte Count; D008297:Male; D010879:Piperazines / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D015848:Interleukin-5; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C434107:mepolizumab; D011239:Prednisolone